FDA yes for Salix's previously delayed Ruconest
This article was originally published in Scrip
Executive Summary
Salix Pharmaceuticals has received a green light from the US FDA to market Ruconest (recombinant C1 esterase inhibitor) for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE).